DCL B Prox10 Anti-Blemish Wash (Benzoyl Peroxide 10%), 200 ml/6.7 fl.oz. Dermatologic Cosmetic La...
FDA Drug Recall #D-0084-2021 — Class II — October 9, 2020
Recall Summary
| Recall Number | D-0084-2021 |
| Classification | Class II — Moderate risk |
| Date Initiated | October 9, 2020 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Milbar Laboratories, Inc. |
| Location | East Haven, CT |
| Product Type | Drugs |
| Quantity | 7,591 bottles |
Product Description
DCL B Prox10 Anti-Blemish Wash (Benzoyl Peroxide 10%), 200 ml/6.7 fl.oz. Dermatologic Cosmetic Laboratories, East Haven, CT 06512 USA, UPC 0357486500853
Reason for Recall
GMP Deviations
Distribution Pattern
Product was distributed throughout the United States, including Puerto Rico and internationally.
Lot / Code Information
Lot # MV098-4, Exp. Date Dec-21 Lot #: JW995, Exp. Date Sep-22 Lot #: Fx381, Exp. Date Jun-23
Other Recalls from Milbar Laboratories, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0087-2021 | Class II | DCL T Shampoo for Hair and Body ( Solution Coal... | Oct 9, 2020 |
| D-0096-2021 | Class II | Salicylic Acid Shampoo 3%, Bulk Product, 360 Th... | Oct 9, 2020 |
| D-0090-2021 | Class II | (Malin+Goetz) spf 30 face moisturizer (Avobenzo... | Oct 9, 2020 |
| D-0095-2021 | Class II | DCL Clear Skin Anti-Blemish Hydrator (2% Salicy... | Oct 9, 2020 |
| D-0088-2021 | Class II | (Malin + Goetz) dandruff Shampoo Psoriasis and ... | Oct 9, 2020 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.